Antibody-Drug Conjugates:
Next-Generation Linker Technology for IND Submissions
About this webinar
Progressing new bioconjugates or antibody-drug conjugates (ADC) forward from discovery to the investigational new drug (IND) submission stage can be a challenging and cumbersome process. The complexity of drug design as well as the extensive technical, safety, stability and scalability challenges — especially when it comes to the linker — makes it incredibly difficult for developers to navigate the development pathway with speed and ease while still ensuring an effective, high-quality product.
In this webinar, the featured experts will explore key considerations when designing and developing a bioconjugate or ADC and the impactful role that linker technologies play in accelerating and de-risking the development process to the IND submission stage. Based on case studies, the experts will also provide insights into topics such as oligonucleotide design and development, ADC to good manufacturing practice (GMP) requirements and the overall application of developability for ADC lead candidate selection.
Register for this webinar today to gain insights into designing and developing a bioconjugate or ADC and the impactful role of linker technologies in accelerating and de-risking the development process.
Who should attend
- Biopharma CMC
- Biopharma method development
- Biopharma process development
- Biophysical Scientists in government and academia
What you will learn
- How to maximize payload potential via site-specific conjugation
- How to achieve a more uniform drug antibody ratio (DAR) profile and stable attachment
- How to optimize the pharmacokinetics (PK) profile
- How Abzena’s unique ThioBridge conjugation technology improves stability, potency and efficacy
Featured Speakers
Dr. Petra Dieterich
Dr. Petra Dieterich holds a PhD in synthetic organic chemistry and an MBA from Imperial College London. She has more than three decades’ experience working in drug development with a focus on CMC activities and has wide-ranging experience working in a CRO environment and leading projects for biotech companies in the development of APIs for clinical trials and commercial use.
Dr. Nicolas Camper
Dr. Nicolas Camper holds a PhD from Queen’s University Belfast on the synthesis of bisphosphonate conjugates to antibody fragments for applications in oncology. Nicholas has experience in bioconjugation, protein engineering, protein expression in bacterial and mammalian systems as well as synthetic chemistry.
Partner for this event
Abzena
Abzena is as committed to success as you are. We have the capabilities, capacity and knowledge to move your asset forward as carefully and quickly as possible.
Our seasoned professionals offer the kind of personalized service and flexible working relationship that your demanding, time-sensitive programs deserve. We’re not afraid to question assumptions, and not shy about presenting new and better ideas.
And then, we deliver.
With research, development, and cGMP facilities across locations in San Diego, CA, Bristol, PA, and Cambridge, UK, Abzena is fully prepared to move your bioconjugate and biologics programs forward at every step in the process.
Related webinars
More from Abzena.
Assessment of Fc-mediated Functional Activity for the Development of Complex Biologics and Bioconjugates
Mastering the Art of Developing a Successful Bispecific Antibody
Accelerating Early Phase Biologics from the Clinic to Commercialization
Early Therapeutic Antibody Development: Addressing the Challenges to Expedite a CMC Program
Process Development: Getting from Phase I to III
Addressing Immunogenicity Challenges to Select the Best Drug Development Candidate
Oligonucleotide ADC Design and Development – An Emerging Field Building on the Success of ADCs in Cancer
Elements for Smooth Technology Transfers of Biologics Manufacturing Processes
